Medical Food and Nutraceutical Compliance: Building 21 CFR 101.9 and FTC-Defensible Evidence

Medical foods occupy one of the most misunderstood corners of consumer health. They are not dietary supplements, they are not drugs, and they are not conventional foods. Defined under the Orphan Drug Act and 21 CFR 101.9(j)(8), a medical food is intended for the dietary management of a specific disease or condition with distinctive nutritional requirements established by medical evaluation, and used under physician supervision. Nutraceutical and medical food brands that get this category right unlock physician-channel marketing and a more durable substantiation moat. Brands that get it wrong end up with FDA warning letters and class-action exposure. This guide is for nutraceutical, medical food, and clinical-nutrition brands that need their evidence and their label to survive both FDA review and FTC scrutiny. What actually qualifies as a medical food A product is a medical food only when it meets all four FDA criteria: it is a food for oral or tube feeding, labeled for the dietary management of a specific disease, designed for a population with distinctive nutritional requirements established by medical evaluation, and used under physician supervision. "Supports healthy aging" or "for people with low energy" does not qualify. "For the dietary management of phenylketonuria," "for the dietary management of mild cognitive impairment due to Alzheimer's," or "for the dietary management of chronic kidney disease" can qualify when supported by an appropriate evidence base. Clinical evidence for medical food claims The evidence bar for a medical food is meaningfully higher than for a dietary supplement. FDA expects published peer-reviewed clinical evidence demonstrating that the formulation addresses the distinctive nutritional requirement of the target patient population. In practice, that means: A randomized, placebo- or active-controlled human trial in the actual disease population (not healthy adults). Pre-registered primary endpoints aligned with the dietary-management claim. Validated clinical instruments (cognition batteries, kidney function panels, GI symptom indices) appropriate to the indication. Physician-administered or physician-supervised data collection where the indication requires it. Nutraceutical vs. supplement vs. medical food The word "nutraceutical" has no FDA definition — it is a marketing term. In practice, a nutraceutical brand will land in one of three regulatory buckets: dietary supplement (DSHEA, structure-function claims), conventional food (general nutrition labeling), or medical food (21 CFR 101.9(j)(8), dietary-management claims). Pick the regulatory pathway before you finalize the label, the dose, and the clinical study design. The wrong pathway can mean either over-claiming as a supplement or under-utilizing the strongest evidence-based positioning available to you as a medical food. Label and claim architecture Medical food (defensible): "For the dietary management of mild memory loss associated with aging, under physician supervision." Dietary supplement structure-function (defensible with substantiation): "Supports healthy memory and cognitive function." Drug claim (off-limits without approval): "Treats Alzheimer's disease," "prevents dementia," "reverses cognitive decline." How Citruslabs supports medical food and nutraceutical sponsors Citruslabs designs and executes clinical studies for medical food, nutraceutical, and clinical-nutrition brands across cognitive, metabolic, GI, and renal indications. We handle regulatory consult on the supplement-vs-medical-food pathway, IRB submission, recruitment of patients meeting the disease criteria for the targeted dietary-management claim, validated endpoint collection, and a publishable clinical study report that supports both physician-channel marketing and FDA-aligned label claims.